Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 894 participants.

Also called NCT01912677

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 894 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01912677
Other papers using this trial's data
  • Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial Lancet (London, England), 2019-09-21 DOI, PubMed 31378394, PMC6857437 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
India (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01912677. Randomized; no masking; primary purpose treatment. Start 2015-04 (actual); primary completion 2017-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy
Condition
Hypertension in Pregnancy
Condition
Preeclampsia
Intervention (Drug)
Nifedipine
Intervention (Drug)
Labetalol
Intervention (Drug)
Methyldopa
Lead sponsor
Gynuity Health Projects (class: other)
Collaborator
Government Medical College, Nagpur (class: industry)
Collaborator
Daga Memorial Women's Hospital, Nagpur, India (class: other)
Collaborator
University of British Columbia (class: other)
Collaborator
Bill and Melinda Gates Foundation (class: other)

Record details

Record id
cardio:ct-nct01912677
Content hash
0c9015819fd5105ca9db40911b10e3e739c9d85fee716c707d7a0d2835b79ede